Class information for:
Level 1: CILOSTAZOL//CLIN PHARMACOKINET PHARMACODYNAM METAB//CAS 73963 72 1

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
16885 566 31.5 82%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
3413 1150 CILOSTAZOL//CLIN PHARMACOKINET PHARMACODYNAM METAB//AZECINES

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CILOSTAZOL Author keyword 242 57% 51% 290
2 CLIN PHARMACOKINET PHARMACODYNAM METAB Address 15 82% 2% 9
3 CAS 73963 72 1 Author keyword 6 80% 1% 4
4 TRIPLE ANTIPLATELET THERAPY Author keyword 6 58% 1% 7
5 OPC 13013 Author keyword 4 75% 1% 3
6 PHOSPHODIESTERASE 3 INHIBITOR Author keyword 3 33% 1% 8
7 MED I EM TISSUE REGENERAT Address 3 15% 3% 16
8 BULK PHARMACEUT CHEM Address 2 67% 0% 2
9 CILOSTAZOL CLINICAL STUDIES Author keyword 2 67% 0% 2
10 K 134 Author keyword 2 67% 0% 2

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CILOSTAZOL 242 57% 51% 290 Search CILOSTAZOL Search CILOSTAZOL
2 CAS 73963 72 1 6 80% 1% 4 Search CAS+73963+72+1 Search CAS+73963+72+1
3 TRIPLE ANTIPLATELET THERAPY 6 58% 1% 7 Search TRIPLE+ANTIPLATELET+THERAPY Search TRIPLE+ANTIPLATELET+THERAPY
4 OPC 13013 4 75% 1% 3 Search OPC+13013 Search OPC+13013
5 PHOSPHODIESTERASE 3 INHIBITOR 3 33% 1% 8 Search PHOSPHODIESTERASE+3+INHIBITOR Search PHOSPHODIESTERASE+3+INHIBITOR
6 CILOSTAZOL CLINICAL STUDIES 2 67% 0% 2 Search CILOSTAZOL++CLINICAL+STUDIES Search CILOSTAZOL++CLINICAL+STUDIES
7 K 134 2 67% 0% 2 Search K+134 Search K+134
8 AB INDEX 1 50% 0% 2 Search AB+INDEX Search AB+INDEX
9 PERIPHERAL ARTERIAL OCCLUSION DISEASE PAOD 1 100% 0% 2 Search PERIPHERAL+ARTERIAL+OCCLUSION+DISEASE+PAOD Search PERIPHERAL+ARTERIAL+OCCLUSION+DISEASE+PAOD
10 PLETAALR 1 100% 0% 2 Search PLETAALR Search PLETAALR

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CHROMOSOME 10 PHOSPHORYLATION 31 92% 2% 12
2 EXPERIMENTAL THROMBOSIS 20 59% 4% 22
3 PHOSPHODIESTERASE INHIBITOR 15 27% 9% 49
4 TREATING INTERMITTENT CLAUDICATION 12 75% 2% 9
5 PHOSPHODIESTERASE TYPE 3 9 67% 1% 8
6 CILOSTAZOL 8 19% 7% 40
7 AMP PHOSPHODIESTERASE INHIBITOR 6 80% 1% 4
8 RECEPTOR GAMMA TRANSCRIPTION 6 80% 1% 4
9 REDUCES LATE RESTENOSIS 6 47% 2% 9
10 III INHIBITOR 5 42% 2% 10

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention 2008 64 35 71%
Efficacy of Cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials 2009 46 43 60%
The pharmacology of cilostazol 2002 70 16 94%
Cilostazol as a unique antithrombotic agent 2003 100 132 56%
Cilostazol (Pletal (R)): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake 2001 92 70 64%
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin 2011 14 26 69%
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons 2014 3 45 44%
CILOSTAZOL 1993 50 22 77%
Cilostazol for intermittent claudication 2014 2 31 48%
Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics 1999 32 3 100%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CLIN PHARMACOKINET PHARMACODYNAM METAB 15 82% 1.6% 9
2 MED I EM TISSUE REGENERAT 3 15% 2.8% 16
3 BULK PHARMACEUT CHEM 2 67% 0.4% 2
4 ADV PHARMACOL 2 50% 0.5% 3
5 CLIN PK PD METAB 1 50% 0.4% 2
6 GEFASSZENTRUM OBERRHEIN MANNHEIM SPEYER 1 50% 0.4% 2
7 NEW DRUG DISCOVERY 1 1 16% 1.1% 6
8 EXECUT DEANS OFF 1 40% 0.4% 2
9 MERIDIAN STRUCT MED 1 11% 1.4% 8
10 PHARMACOL TEAM 1 33% 0.4% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000159004 MOUSE LYMPHOID NEOPLASMA P 388//MOUSE MAMMARY CARCINOMA FM 3A//HUMAN HISTIOCYTIC LYMPHOMA U 937
2 0.0000105677 IBUDILAST//CAS 50847 11 5//221 MIYAMA
3 0.0000092325 PROBUCOL//AGI 1067//SUCCINOBUCOL
4 0.0000091361 ANKLE BRACHIAL INDEX//INTERMITTENT CLAUDICATION//PERIPHERAL ARTERIAL DISEASE
5 0.0000086544 CLOPIDOGREL//PRASUGREL//TICAGRELOR
6 0.0000080831 CHRONIC CEREBRAL HYPOPERFUSION//PERMANENT OCCLUSION OF BILATERAL COMMON CAROTID ARTERIES//CEREBRAL HYPOPERFUSION
7 0.0000062263 VASCULAR SURGERY PROCEDURES//ARTERIOSCLEROSIS SURGERY//BOA TRIAL OFF
8 0.0000056108 ROLIPRAM//PDE4//PHOSPHODIESTERASE
9 0.0000050751 TRANSIENT ISCHEMIC ATTACK//ABCD2 SCORE//TIA
10 0.0000048193 I EM NEURODEGENERAT BRAIN//BERAPROST SODIUM//NEONATE INFANT PATHOL